May 21 24, Santa Margherita Ligure - Portofino. Chairmen. 3 rd International Conference. Angelo M. Carella Felicetto Ferrara Enrica Morra

Transcription

1 SECTION OF HEMATOLOGY 3 rd International Conference LEUKEMIA2014 Santa Margherita Ligure - Portofino May 21 24, 2014 Chairmen Angelo M. Carella Felicetto Ferrara Enrica Morra

2 3 rd International Conference LEUKEMIA 2014 This Conference will be dedicated to Prof. John M. Goldman PRESENTATION The Conference, with the participation of the most important International and Italian experts, wants to provide an update on the most innovative aspects of cellular and molecular biology, treatment of acute and chronic leukemias, myelodysplastic syndromes and Ph-negative chronic myeloproliferative syndrome. One section will be dedicated to the new drugs in onco-hematology. ADDRESSED TO Physicians specialized in Hematology, Oncology and Biologists. OFFICIAL LANGUAGE The meeting will be held in English. No simultaneous translation will be provided. 2

3 PROGRAMME WEDNESDAY, MAY 21 NEW DRUGS IN ONCO-HEMATOLOGY (not for CME credits) Chairmen: Massimo Federico Pier Luigi Zinzani Celgene pipeline and in earlydevelopment programs James Carmichael Novelties in strategic approach to chronic hematological malignancies Alf Bernhardt An update of Brentuximab Vedotin and its future prospective Andreas Engert New perspectives in acute leukemias Giovanni Martinelli Arsenic trioxide: many stories about an old product Giuseppe Rossi New prospective in hematology Daniele Alberti The use of an adaptive trial design in a phase III trial of Vosaroxin and Cytarabine in relapsed and refractory AML Adam Craig New drugs anti-leukemia Danilo Perrotti CHALLENGES IN PHILADELPHIA- POSITIVE LEUKEMIAS Chairmen: Robin Foà Angelo M. Carella Introduction Robin Foà Current clinical options in Ph+ ALL Robin Foà Early and deep molecular response predictive of long term outcome in Ph+ leukemias Giovanni Martinelli Ponatinib: bridge to transplant and post transplant clinical strategies Fabio Ciceri Conclusions and general Angelo M. Carella Round Table BONE MARROW TRANSPLANTATION IN LEUKEMIAS: NEW PERSPECTIVES Chairmen: Alberto Bosi Andrea Bacigalupo Immunologic pressure after transplant and HLA Fabio Ciceri 3

4 Unrelated donor transplant for leukemia Jane F. Apperley Finding a donor for most eligible patients William Arcese HDCT in MDS: indications, timing and optimization of the results. What s new? Emanuele Angelucci End of session THURSDAY, MAY Opening Ceremony ACUTE MYELOID LEUKEMIAS IN 2014: SOME UNRESOLVED ISSUES Chairmen: Jacob M. Rowe Sergio Amadori 8.15 Introduction Jacob M. Rowe 8.20 The increasing role of mutations and genomics Brunangelo Falini 8.40 The increasing clinical relevance of minimal residual disease Gert J. Ossenkoppele 9.00 Is there a role of adjunctive therapy to standard 3+7? Alan K. Burnett 9.20 Optimal non-transplant post remission therapy Jacob M. Rowe 9.40 Allogeneic transplant for older patients: GITMO experience Alessandro Rambaldi Therapy of a fit 70 years old individual Richard F. Schlenk APL in 2014: next challenges for the final cure Francesco Lo Coco Conclusions and general Sergio Amadori Coffee break Plenary Lecture Regulation of self renewal in cancer stem cells Pier Giuseppe Pelicci Presented by: Roberto M. Lemoli SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL NEOPLASIAS Chairman: Francesco Menichetti Pathophysiology and clinical features Valerio Del Bono Infections with multidrugresistant pathogens Gian Maria Rossolini 4

5 12.10 Neutropenic Enterocolitis: a life threatening complications Edoardo Benedetti IgM concentrated: rationale for its use in hematology in the era of bad bugs Fabio Tumietto IgM enriched immunoglobulins and defribotide after allogenic hematopoietic transplantation in acute leukemia Giuseppe Milone Lunch CHRONIC LYMPHOCYTIC LEUKEMIA Chairmen: Enrica Morra Giovanni Pizzolo Introduction Manlio Ferrarini NoTCH1 mutations: pathogenesis and clinical significance Davide Rossi Transforming response prediction to chemo-immunotherapy using genome technologies Anna Schuh Do the next molecular markers have an impact in treatment strategy? Gianluca Gaidano First line therapy: which are the options today? Marco Montillo Ultra-high risk patients: definition and treatment pathway in the era of novel drug landscape Peter Dreger Break Second line therapy: what are the options today? Véronique Leblond Immunotherapeutic strategies including transplant John G. Gribben A look at the future: new options? George Follows Conclusions and general Enrica Morra, Giovanni Pizzolo FRIDAY, MAY 23 CHRONIC MYELOID LEUKEMIAS: WHAT IS NEW? Chairmen: Rudiger Hehlmann Angelo M. Carella 8.00 Introduction Rudiger Hehlmann 8.05 The basis for clinical heterogeneity Giuseppe Saglio 8.25 Initial choice of therapy Michele Baccarani 5

6 Molecular monitoring Andreas Hochhaus 9.05 Alternative approaches in eradicating the malignant clone Richard A. Van Etten 9.25 Early molecular response is predictive of long-term outcome? Susan Branford 9.45 Current clinical options after resistance/intolerance to 1G/2G TKIs Fabrizio Pane Blastic crisis management Rudiger Hehlmann When should we transplant? Jane Apperley Coffee break Safety profiles of different TKIs Carlo Gambacorti-Passerini How will we manage CML in the next decade? Stephen O Brien Conclusions and general Angelo M. Carella NEW MOLECULAR INSIGHTS AND THERAPEUTIC STRATEGIES IN ACUTE LYMPHOCYTIC LEUKEMIA Chairmen: Dieter Hoelzer Felicetto Ferrara Introduction Dieter Hoelzer New markers for the diagnosis of ALL: including NGS? Robin Foà / Sabina Chiaretti Minimal residual disease: comparison of different methods Monika Brüggemann Current treatment results without antibodies Renato Bassan Antibody therapy Dieter Hoelzer Targeted therapy Oliver G. Ottmann Lunch Risk factors and therapy in adult T-ALL Vahid Asnafi Stem cell transplantation Andrea Bacigalupo Conclusions and general Felicetto Ferrara Break MYELODYSPLASTIC SYNDROMES Chairmen: Giorgina Specchia Pellegrino Musto Introduction Giorgina Specchia Classification Pellegrino Musto

7 16.40 Prognostic models to predict survival Valeria Santini Low-risk patients with deletions in chromosome 5 Esther N. Oliva Therapeutic strategies Giorgina Specchia Five years after Azacitidine approval: remaining challenges Thomas Prebet Who should be transplanted and when? Maria Teresa Voso Conclusions and general Pellegrino Musto SATURDAY, MAY Therapeutic challenges in PV and ET patients conventionally classified at low-risk for thrombosis Tiziano Barbui Prefibrotic myelofibrosis: a diagnosis that counts Giovanni Barosi Are we ready for treatment recommendations with Ruxolitinib in myelofibrosis? Jean-Jacques Kiladjian Deciding hematopoietic stemcell transplant in myelofibrosis Nicolaus Kröger Conclusions and general Marco Gobbi End of the conference PH-NEGATIVE MYELOPROLIFERATIVE SYNDROMES Chairmen: Tiziano Barbui Marco Gobbi 9.00 Introduction Tiziano Barbui 9.10 Molecular diagnosis of MPNs in practice Robert Kralovics 9.30 Molecular prognostic profiling in primitive myelofibrosis Alessandro Vannucchi 7

8 SCIENTIFIC COORDINATORS Angelo Michele Carella U.O.C. Ematologia I IRCCS A.O.U. San Martino-IST Genova (I) Felicetto Ferrara U.O. Ematologia e Trapianto di Midollo Osseo A.O. A. Cardarelli Napoli (I) Enrica Morra U.O. Ematologia e Trapianto di Midollo A.O. Ospedale Niguarda Cà Granda Milano (I) SPEAKERS AND CHAIRMEN 8 Daniele Alberti, Origgio, MI (I) Sergio Amadori, Roma (I) Emanuele Angelucci, Cagliari (I) Jane F. Apperley, London (UK) William Arcese, Roma (I) Vahid Asnafi, Paris (F) Michele Baccarani, Bologna (I) Andrea Bacigalupo, Genova (I) Tiziano Barbui, Bergamo (I) Giovanni Barosi, Pavia (I) Renato Bassan, Venezia (I) Edoardo Benedetti, Pisa (I) Alf Bernhardt, Basel (CH) Alberto Bosi, Firenze (I) Susan Branford, Adelaide (AUS) Monika Brüggemann, Kiel (D) Alan K. Burnett, Cardiff (UK) James Carmichael, Seville (S) Sabina Chiaretti, Roma (I) Fabio Ciceri, Milano (I) Adam Craig, South San Francisco (USA) Valerio Del Bono, Genova (I) Peter Dreger, Heidelberg (D) Andreas Engert, Cologne (D) Brunangelo Falini, Perugia (I) Massimo Federico, Modena (I) Manlio Ferrarini, Genova (I) George Follows, Cambridge (UK) Robin Foà, Roma (I) Gianluca Gaidano, Novara (I) Carlo Gambacorti-Passerini, Monza (I) Marco Gobbi, Genova (I) John G. Gribben, London (UK) Rudiger Hehlmann, Heidelberg (D) Andreas Hochhaus, Jena (D) Dieter Hoelzer, Frankfurt (D) Jean-Jacques Kiladjian, Paris (F) Robert Kralovics, Vienna (A) Nicolaus Kröger, Hamburg (D) Véronique Leblond, Paris (F) Roberto M. Lemoli, Genova (I) Francesco Lo Coco, Roma (I) Giovanni Martinelli, Bologna (I) Francesco Menichetti, Pisa (I) Giuseppe Milone, Catania (I) Marco Montillo, Milano (I) Pellegrino Musto, Rionero in Vulture, PZ (I) Stephen O Brien, Newcastle (UK) Esther Natalie Oliva, Reggio Calabria (I) Gert J. Ossenkoppele, Amsterdam (NL) Oliver G. Ottmann, Frankfurt (D) Fabrizio Pane, Napoli (I) Pier Giuseppe Pelicci, Milano (I) Danilo Perrotti, Baltimore (USA) Giovanni Pizzolo, Verona (I) Thomas Prebet, Marseille (F) Alessandro Rambaldi, Bergamo (I) Davide Rossi, Novara (I) Giuseppe Rossi, Brescia (I) Gian Maria Rossolini, Siena (I) Jacob M. Rowe, Jerusalem (IL) Giuseppe Saglio, Orbassano, TO (I) Valeria Santini, Firenze (I) Richard F. Schlenk, Ulm (D) Anna Schuh, Oxford (UK) Giorgina Specchia, Bari (I) Fabio Tumietto, Bologna (I) Richard A. Van Etten, Orange CA, (USA) Alessandro M. Vannucchi, Firenze (I) Maria Teresa Voso, Roma (I) Pier Luigi Zinzani, Bologna (I)

9 CME Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign 16,5 CME credits to the activity The Meeting is addressed to Physicians specialized in Hematology, Oncology and Biologists. It will not be possible to give Credits to physicians specialized in different fields. The credit certification is subject to: - attendance at the entire Meeting - the completion of the Meeting evaluation form - the completion of the final questionnaire (at least 75% of correct answers) REGISTRATION The registration fee is 150,00 tax free. To register, please send: - registration form duly filled out (even when sponsored by a Pharmaceutical Company) - privacy statement and consent regarding personal information (back of the form) - payment to Accademia Nazionale di Medicina Via Martin Piaggio 17/ Genova fax registration@accmed.org, by May 12, 2014 Online registration is possible on the website By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat. Incomplete registration will not be admitted. The registration will be confirmed by , please indicate your address on the registration form. Cancellation - If the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee. - In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Cancellations after that deadline will not be refounded. 9

10 VENUE Grand Hotel Miramare Via Milite Ignoto, 30 Santa Margherita Ligure (GE), Italy How to reach the meeting venue: By train the nearest train station is Santa Margherita Ligure, located 1,5 km from the meeting venue. By car From A12 motorway please take Rapallo exit an then follow signs to Santa Margherita Ligure (about 5 km) and continue on the road along the seaside. Grand Hotel Miramare is located just a few meters after S. Margherita port. By plane Genoa airport is located 30 km away from the meeting venue. PROMOTED BY ACCADEMIA NAZIONALE DI MEDICINA General Manager: Stefania Ledda ORGANIZING PARTNER Forum Service Via Martin Piaggio 17/ Genoa Information and registration Ph Fax registration@accmed.org Hotel booking Ph Fax booking@accmed.org 10

11 WITH THE PATRONAGE OF Società Italiana di Ematologia - SIE Società Italiana di Ematologia Sperimentale - SIES 11

12 With the unconditioned contribution of Platinum Sponsor Gold Sponsor Silver Sponsor Bronze Sponsor